Last updated: September 23, 2026
Tivozanib hydrochloride, marketed as Fotivda, is a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor developed for advanced renal cell carcinoma. Its commercial position is defined by a narrow U.S. label, late-line use, a differentiated tolerability profile, and limited competition within the post-VEGF treatment setting. The drug generated meaningful commercial revenue for AVEO Pharmaceuticals before LG Chem acquired the company in 2023, but it remains a niche oncology asset rather than a broad-market checkpoint or first-line therapy.
What is tivozanib hydrochloride and how is Fotivda used?
Tivozanib is an oral small-molecule inhibitor of VEGFR-1, VEGFR-2 and VEGFR-3. Fotivda is supplied as 1.34 mg capsules, equivalent to 1.5 mg of tivozanib hydrochloride, with a recommended schedule of 1.34 mg once daily for 21 consecutive days followed by seven days without treatment.
The U.S. Food and Drug Administration approved Fotivda on March 10, 2021, for adults with relapsed or refractory advanced renal cell carcinoma who previously received at least two systemic therapies. The approval was based primarily on the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced RCC after at least two prior systemic regimens.[1]
In Europe, the European Commission granted marketing authorization in 2017 for adults with advanced RCC who had not previously received a VEGFR or mTOR inhibitor, or who had disease progression after prior cytokine therapy.[2] The European indication and commercial positioning have differed from the narrower U.S. post-two-line indication.
Key product facts
| Attribute |
Data |
| Active ingredient |
Tivozanib hydrochloride |
| Brand |
Fotivda |
| Dosage form |
Oral capsule |
| U.S. sponsor at approval |
AVEO Pharmaceuticals |
| Current corporate owner |
LG Chem, through AVEO Pharmaceuticals |
| U.S. approval |
March 10, 2021 |
| U.S. indication |
Advanced RCC after at least two prior systemic therapies |
| Recommended dose |
1.34 mg once daily, 21 days on and 7 days off |
| FDA pathway |
New Drug Application |
| Product type |
Small molecule |
| Biosimilar pathway |
Not applicable |
| Primary commercial market |
U.S. advanced RCC |
How large is the tivozanib market?
Tivozanib addresses a narrower market than first-line RCC combinations. The drug competes mainly in later-line advanced RCC, where treatment decisions depend on prior exposure to immune checkpoint inhibitors, VEGF-directed therapies and, in some cases, mTOR or HIF-2α agents.
The broader U.S. kidney cancer market includes:
- Pembrolizumab combinations in first-line disease.
- Nivolumab plus ipilimumab in intermediate- and poor-risk first-line disease.
- Cabozantinib and lenvatinib-based regimens.
- Axitinib-based treatment.
- Belzutifan for selected patients after prior therapy.
- Tivozanib for patients with advanced RCC after at least two systemic regimens.
Tivozanib does not directly compete for the full first-line RCC population. Its addressable population is reduced by treatment attrition, prior therapy requirements and physician preference for alternative targeted agents.
Why tivozanib has commercial relevance
Tivozanib has several attributes that support continued use in later-line RCC:
- It has a selective VEGFR profile.
- The TIVO-3 trial showed longer progression-free survival than sorafenib in a heavily pretreated population.
- Its toxicity profile can support treatment continuation in patients who have already received multiple therapies.
- It is administered orally and does not require infusion infrastructure.
- It remains relevant after exposure to immune checkpoint therapy, which is common in current RCC treatment sequences.
The principal commercial limitation is its position late in the treatment pathway. Earlier-line regimens capture most treatment value and physician attention, while later-line patients face declining performance status and shorter treatment duration.
What were Fotivda’s revenues before LG Chem acquired AVEO?
AVEO reported rapid product revenue growth after the U.S. launch, although the company remained dependent on one marketed product and continued to report operating losses during its independent period.
Public company filings reported the following approximate trajectory:
| Period |
Commercial development |
Reported financial direction |
| 2021 |
U.S. launch following FDA approval |
Initial product revenue generation |
| 2022 |
Expansion of U.S. commercial activity |
Net product revenue exceeded $100 million |
| 2023 |
LG Chem acquisition completed |
AVEO ceased operating as an independent public company |
| 2024 onward |
Product managed within LG Chem’s oncology portfolio |
Standalone Fotivda revenue disclosure is limited |
AVEO reported approximately $100 million in net product revenue in 2022, compared with substantially lower revenue during the initial U.S. launch period.[3] The growth reflected increased prescribing, payer access and expansion of the U.S. commercial base.
The revenue profile was commercially attractive for a specialty oncology product but insufficient to support a large independent infrastructure without continued growth or broader label expansion. AVEO’s financial position combined:
- Rising Fotivda sales.
- High sales and marketing costs.
- Continued research and development spending.
- A concentrated revenue base.
- Dependence on one principal commercial asset.
LG Chem agreed to acquire AVEO in 2023 in a transaction valued at approximately $571 million, or $15 per share.[4] The transaction gave LG Chem control of Fotivda and AVEO’s oncology development platform.
Why did LG Chem acquire AVEO and tivozanib?
LG Chem’s acquisition strategy was based on adding a commercial oncology product and establishing a U.S. pharmaceutical platform. Tivozanib provided immediate revenue, an FDA-approved product and a presence in an oncology market with established treatment demand.
The transaction had four commercial objectives:
- Acquire a marketed oncology asset rather than relying only on pipeline programs.
- Expand LG Chem’s U.S. pharmaceutical infrastructure.
- Use AVEO’s commercial organization and regulatory capabilities.
- Develop additional indications or combinations around tivozanib and related oncology assets.
The acquisition also reduced AVEO’s financing risk. Before the transaction, the company’s prospects depended heavily on continued Fotivda adoption and successful clinical development. Under LG Chem, the product has access to a larger corporate balance sheet, although public reporting no longer provides the same level of standalone product economics.
How does tivozanib compare with competing renal cell carcinoma drugs?
Tivozanib’s closest commercial comparisons are other oral VEGF pathway inhibitors rather than biologic checkpoint inhibitors.
| Drug |
Main mechanism |
Typical market position |
Commercial distinction |
| Fotivda |
Selective VEGFR inhibitor |
Later-line advanced RCC |
Narrow U.S. label and post-two-line use |
| Cabometyx |
VEGFR, MET, AXL and other kinase inhibition |
First-line combinations and later-line RCC |
Broader use and larger commercial footprint |
| Lenvima |
VEGFR and multikinase inhibition |
Combination with pembrolizumab or everolimus |
Strong combination positioning |
| Inlyta |
VEGFR inhibitor |
First-line combination and later-line use |
Established use with immunotherapy |
| Welireg |
HIF-2α inhibitor |
Selected previously treated RCC patients |
Distinct mechanism and biomarker-related positioning |
| Opdivo/Yervoy |
Immune checkpoint inhibition |
First-line RCC |
Intravenous immunotherapy and broad treatment impact |
Tivozanib’s main advantage is selectivity and its clinical use in heavily pretreated patients. Its main disadvantage is that cabozantinib, lenvatinib-based regimens and belzutifan occupy important portions of the same later-line treatment landscape.
What is the FDA regulatory status of Fotivda?
Fotivda has full FDA approval for its approved indication. The approval was supported by the randomized TIVO-3 study, which enrolled patients with metastatic RCC after at least two prior systemic regimens.
The FDA label identifies hypertension, fatigue, diarrhea, decreased appetite, nausea, dysphonia and hypothyroidism among clinically relevant adverse reactions. Hypertension and other class-related toxicities require monitoring and dose management.[1]
The U.S. label does not establish Fotivda as a first-line treatment. Any expansion into earlier-line RCC would require additional clinical and regulatory support. Such an expansion could materially increase the addressable market, but the available commercial base has remained centered on later-line treatment.
What patents protect tivozanib and when could generic competition emerge?
Fotivda is a small-molecule product, so its U.S. exclusivity depends on patents, FDA regulatory exclusivity and potential generic applications under the Abbreviated New Drug Application pathway. Biosimilar competition does not apply.
Public patent and regulatory records indicate that protection is based on a combination of:
- Composition-of-matter and chemical compound claims.
- Pharmaceutical composition claims.
- Treatment-method claims for RCC.
- Dosing and administration claims.
- Manufacturing or solid-form protection.
The earliest basic compound protection is generally less important than the later Orange Book-listed patents that may control generic launch timing. Generic applicants can challenge listed patents through Paragraph IV certifications, which can trigger litigation and potentially a 30-month stay of approval under the Hatch-Waxman framework.
Orange Book and Paragraph IV risk
The commercial risk assessment requires separating three dates:
- FDA regulatory exclusivity expiration.
- Orange Book patent expiration.
- The earliest practical generic launch date after litigation or settlement.
Tivozanib does not have the patent-duration profile of a newly launched biologic. Its later commercial launch in the United States did not reset the original chemical patent term. The most important patent risks therefore concern the remaining term of listed patents and the strength of method-of-use or formulation claims.
No widely reported U.S. generic launch has materially disrupted Fotivda sales as of the latest publicly available corporate disclosures. A future Paragraph IV challenge would likely focus on obviousness, written description, enablement, anticipation or noninfringement of listed treatment and formulation claims.
What formulation and method-of-use patents protect Fotivda?
Formulation protection can be commercially important for tivozanib because the product is an oral capsule with defined dosage strengths and a controlled treatment schedule. However, formulation patents are usually more vulnerable than a valid, enforceable composition-of-matter patent if the generic can design around the claimed formulation.
Method-of-use protection may cover treating advanced RCC in defined prior-treatment populations or using specific dosing schedules. These claims can delay a fully substitutable generic only when:
- The claims are listed in the Orange Book.
- The generic applicant must certify against them.
- The patent survives litigation.
- The generic label cannot omit the protected use.
A generic applicant may pursue a skinny label that removes a patented indication. This creates a more complex entry scenario than a full-label generic launch.
What is the geographic coverage of tivozanib?
Tivozanib has the strongest regulatory and commercial presence in the United States and Europe. The European product has been commercialized through regional licensing and specialty pharmaceutical arrangements, including EUSA Pharma-related commercialization.
Geographic performance differs because:
- The European indication was authorized earlier than the U.S. indication.
- Pricing and reimbursement systems vary substantially.
- Some European markets use centralized or regional purchasing.
- The United States has higher branded oncology pricing but greater payer and specialty-pharmacy complexity.
- Commercial rights have been divided among partners in certain territories.
LG Chem’s ownership of AVEO gives it control over the U.S. product platform, while historical licensing arrangements and regional commercialization rights may continue to affect non-U.S. economics.
How strong is the tivozanib patent estate?
Tivozanib’s patent estate is commercially useful but not unassailable.
Strengths
- FDA-approved product with defined clinical use.
- Later-line RCC indication supported by randomized data.
- Potentially layered protection across compound, formulation, dosing and treatment methods.
- Specialty oncology market with relatively high barriers to immediate generic substitution.
Weaknesses
- Small-molecule generic entry is structurally easier than biosimilar entry.
- Later-issued method and formulation claims can face obviousness challenges.
- The U.S. label is narrow, limiting the value of certain method-of-use claims.
- The product’s commercial base is concentrated in one disease area.
- A generic may seek a limited label or rely on noninfringing treatment instructions.
The estate should therefore be viewed as a time-limited barrier rather than a permanent moat. The most important commercial question is whether listed patents extend effective exclusivity into the early-to-mid 2030s or whether generic entry becomes possible earlier through litigation or a settlement.
What generic launch scenarios exist for Fotivda?
Three scenarios are commercially relevant.
Scenario 1: No near-term Paragraph IV challenge
Fotivda retains branded pricing and physician familiarity. Revenue grows modestly with the later-line RCC market but remains constrained by the narrow label.
Scenario 2: Patent litigation followed by delayed entry
A generic applicant files a Paragraph IV certification, and the sponsor sues within the statutory period. Entry is delayed until patent expiration, a court decision or a negotiated settlement. This scenario preserves branded revenue for several years but increases legal costs and pricing pressure.
Scenario 3: Early settlement or successful invalidity challenge
Generic entry occurs before the latest asserted patent expiration. Revenue can decline rapidly because oral oncology products are vulnerable to payer substitution and specialty-pharmacy substitution once an approved generic is available.
The magnitude of erosion would depend on the number of entrants. One generic typically creates less immediate price compression than multiple competing manufacturers, but branded market share can fall quickly when reimbursement policies favor substitution.
What licensing deals and commercial partnerships affect tivozanib?
Tivozanib was developed through relationships involving AVEO and Kyowa Hakko Kirin, with regional commercialization arrangements supporting the European market. EUSA Pharma has been associated with commercialization rights in territories outside the United States.
The LG Chem acquisition changed the ownership structure but did not eliminate the importance of territorial rights, royalty obligations and legacy development agreements. These arrangements affect net revenue because gross product sales may be reduced by:
- Royalty payments.
- Milestone obligations.
- Distribution fees.
- Co-promotion costs.
- Returns and rebates.
- Regional pricing controls.
The U.S. business is the most strategically important asset because the FDA approval supports a direct commercial model and higher branded oncology pricing.
What litigation and settlement risks affect Fotivda?
The central litigation risk is future Hatch-Waxman patent litigation rather than product-liability litigation. A Paragraph IV filing could generate:
- A statutory 30-month stay of FDA approval.
- District-court litigation over listed patents.
- Potential settlement with an agreed generic launch date.
- A change in the effective exclusivity period.
- Royalty or supply arrangements.
No publicly established settlement has become the defining event for Fotivda’s U.S. market access as of the latest available disclosures. The absence of a major generic launch keeps the current commercial focus on lifecycle management and market development rather than immediate erosion defense.
What is the financial outlook for tivozanib?
Fotivda’s financial trajectory has three phases:
- Pre-launch and development, when AVEO carried substantial operating losses.
- Post-approval growth, when U.S. product revenue increased rapidly from a small launch base.
- Post-acquisition integration, when product economics became part of LG Chem’s broader pharmaceutical reporting.
The product’s upside depends on market expansion rather than on a large increase in price. The most valuable growth opportunities are:
- Earlier-line RCC studies.
- Combination therapy with immuno-oncology agents.
- Greater use after checkpoint inhibitor exposure.
- Improved physician awareness of the TIVO-3 data.
- International market expansion.
- Lifecycle formulations or dosing improvements.
The principal downside risks are:
- Limited patient numbers in the approved U.S. population.
- Competition from cabozantinib, lenvatinib, belzutifan and immunotherapy sequences.
- Generic entry.
- Weak uptake in heavily pretreated patients.
- Dependence on one principal indication.
- Limited standalone financial transparency after AVEO became part of LG Chem.
Fotivda is best characterized as a revenue-generating specialty oncology asset with moderate growth potential and meaningful patent-driven downside risk. It is unlikely to achieve the scale of a first-line RCC checkpoint combination without a significant label expansion.
Key Takeaways
- Tivozanib hydrochloride is marketed in the United States as Fotivda for advanced RCC after at least two prior systemic therapies.
- The FDA approved Fotivda in March 2021; European approval came in 2017.
- AVEO reported more than $100 million in net product revenue in 2022 before LG Chem acquired the company for approximately $571 million in 2023.
- Tivozanib competes mainly in later-line RCC against cabozantinib, lenvatinib, belzutifan and other VEGF-directed therapies.
- The product is a small molecule, so generic rather than biosimilar competition is the relevant market-access risk.
- Its patent estate likely relies on layered compound, formulation, dosing and method-of-use protection.
- The narrow U.S. label limits market size but supports focused specialty-oncology commercialization.
- Future value depends on label expansion, combination development, geographic growth and the timing of any Paragraph IV challenge.
- LG Chem’s ownership improves corporate resources but reduces standalone public visibility into Fotivda revenue and profitability.
FAQs About Tivozanib Hydrochloride and Fotivda
Is tivozanib the same as tivozanib hydrochloride?
Tivozanib hydrochloride is the salt form used in the commercial product. Fotivda capsules contain tivozanib hydrochloride equivalent to the labeled amount of tivozanib.
Is Fotivda a chemotherapy drug?
No. Fotivda is an oral targeted therapy that inhibits VEGF receptors. It is classified as a tyrosine kinase inhibitor, not a conventional cytotoxic chemotherapy.
Can a generic company make tivozanib?
Yes. Tivozanib is a small molecule eligible for an Abbreviated New Drug Application, subject to applicable patent, exclusivity and regulatory requirements.
Does Fotivda have biosimilar competition?
No. Biosimilars apply to biological products. Fotivda is a chemically synthesized small-molecule drug.
What would most increase tivozanib revenue?
A validated earlier-line RCC indication or a successful combination regimen would have the greatest potential to expand the product’s addressable patient population beyond its current late-line niche.
References
-
U.S. Food and Drug Administration. (2021). Fotivda (tivozanib) prescribing information. FDA.
-
European Medicines Agency. (2017). Fotivda: EPAR product information. EMA.
-
AVEO Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
LG Chem Ltd. (2023). LG Chem completes acquisition of AVEO Pharmaceuticals. LG Chem.
-
National Cancer Institute. (2024). Renal cell cancer treatment. National Institutes of Health.
